Skip to Content

Merck & Co Inc

View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation

Merck Posts Strong Q2, Buoyed by Easy Comparisons and Robust Keytruda and Gardasil Gains

Merck reported strong second-quarter results ahead of our projections, but we do not expect any major changes to our fair value estimate based on the minor outperformance. With the strong stock performance over the past few months, we now view the stock as only slightly undervalued, with the market better appreciating the growth potential of the firm’s current portfolio and pipeline, the keys pillars to Merck’s wide moat.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of MRK so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center